TREG EULAR 2025 Rheumatoid Arthritis & Vasculitis

Psoriatic Arthritis Panel: EULAR 2025

Panelists Drs. Aurelie Najm, Eric Ruderman, Nelly Ziade, Jiha Lee and Jack Cush review highlights of PsA abstracts and sessions presented at the 2025 EULAR meeting in Barcelona, Spain.

Spondyloarthritis Panel: Eular 2025

Panelists: Drs. Peter Nash, Yuz Yusof, Antoni Chan, Adela Castro and Jack Cush.

Steroids, Not JAKi, Are the Real Infection Risk

Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain.

Seronegative Arthritis Breakthroughs

Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Psoriatic Arthritis", presented at EULAR 2025 in Barcelona, Spain.

JAK Safety Update

Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.

Who/When to Treat Clinically Suspect Arthralgia

Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)

Hidradenitis Suppurativa: What Lies Beneath?

Dr. David Liew reports on abstract POS1237 presented at the EULAR 2025 meeting in Barcelona, Spain.

The Value of Kidney Biopsy in Autoimmune Diseases

Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.

ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA

At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.